---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091130"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T09:54:01.053157+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharma Q2 net loss $4.3M; cash only into Q4 2023; ELX-02 positive biopsy data

## Summary
- Net loss of $4.3M ($1.96 EPS) vs $10.6M ($4.90 EPS) in prior-year quarter.
- Cash $4.3M at June 30; raised $1.7M gross via ATM program post-quarter.
- All 3 patients on ELX-02 showed improved podocyte foot process effacement in kidney biopsies; company plans pivotal Alport trial pending funding.
- FDA cleared IND for ZKN-013 SAD study in RDEB; first dosing expected by end 2023.
- Nasdaq extended compliance deadline for $35M market value listing rule to October 9, 2023.

## SEC filing metadata
- accession: 0001104659-23-091130
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923091130/0001104659-23-091130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923091130/tm2323659d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091130
- JSON: https://secwatch.observer/filing/0001104659-23-091130.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091130.txt

## Key facts
- Earnings Releases
  Eloxx Pharmaceuticals, Inc. reported financial results for the three months ended June 30, 2023.
  - Period: the three months ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923091130/0001104659-23-091130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.